Rimegepant is already FDA-approved for acute treatment of migraine and preventive treatment of episodic migraine in adults.

A novel treatment for irritable bowel syndrome (IBS) is on the horizon, with the discovery that two specific gut microbes ...

The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously. The updated outlook comes as Ibsrela continues to ...

Research from the University of Gothenburg, Sweden, clarifies the complex interaction between gut bacteria and irritable ...

The American College of Gastroenterology estimates that between 10% and 15% of American adults suffer from irritable bowel syndrome but that only about 7% have received a diagnosis for it. The cause ...